First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19.
作者信息
Stahl Klaus, Bode Christian, David Sascha
机构信息
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Department of Anaesthesiology and Critical Care, University Medicine Bonn, Bonn, Germany.
出版信息
Crit Care. 2020 Jun 18;24(1):363. doi: 10.1186/s13054-020-03070-7.
Abstract
摘要
相似文献
1
First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19.
Crit Care. 2020 Jun 18;24(1):363. doi: 10.1186/s13054-020-03070-7.
2
Therapeutic Plasma Exchange-Neutralizing Antibody Combination Therapy for Severe Coronavirus Disease 2019.
J Infect Dis. 2020 Jul 6;222(3):509-510. doi: 10.1093/infdis/jiaa312.
3
Response to Malkovsky.
J Infect Dis. 2020 Jul 6;222(3):510-511. doi: 10.1093/infdis/jiaa313.
4
Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19.
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12526-12527. doi: 10.1073/pnas.2006691117. Epub 2020 May 12.
5
Therapeutic plasma exchange as a rescue therapy in patients with coronavirus disease 2019: a case series.
Pol Arch Intern Med. 2020 May 29;130(5):455-458. doi: 10.20452/pamw.15340. Epub 2020 May 7.
6
Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure.
Crit Care. 2020 May 15;24(1):226. doi: 10.1186/s13054-020-02943-1.
7
A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19.
Crit Care. 2020 Apr 2;24(1):128. doi: 10.1186/s13054-020-2836-4.
8
Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome.
J Formos Med Assoc. 2020 Dec;119(12):1888-1889. doi: 10.1016/j.jfma.2020.07.016. Epub 2020 Jul 13.
9
Reply to Letter to the Editor: Therapeutic plasma exchange resolving COVID-19 related ARDS.
J Formos Med Assoc. 2020 Dec;119(12):1890-1892. doi: 10.1016/j.jfma.2020.07.031. Epub 2020 Jul 28.
10
COVID-19 Pandemic Hemoperfusion Therapy Versus Plasma Exchange Therapy in Intensive Care.
Iran J Allergy Asthma Immunol. 2020 May 17;19(S1):7-9. doi: 10.18502/ijaai.v19i(s1.r1).2848.
引用本文的文献
1
Plasma Adsorption with the MTx.100 Column in Critically Ill COVID-19 Patients: A Prospective Study and Propensity Score Analysis.
J Intensive Care Med. 2025 Mar;40(3):314-319. doi: 10.1177/08850666241280031. Epub 2024 Sep 12.
2
A randomised controlled trial of plasma exchange compared to standard of care in the treatment of severe COVID-19 infection (COVIPLEX).
Sci Rep. 2024 Jul 23;14(1):16876. doi: 10.1038/s41598-024-67028-3.
3
Plasma exchange and COVID 19.
Transfus Apher Sci. 2022 Dec;61(6):103598. doi: 10.1016/j.transci.2022.103598. Epub 2022 Nov 12.
4
Acute Kidney Injury and Blood Purification Techniques in Severe COVID-19 Patients.
J Clin Med. 2022 Oct 25;11(21):6286. doi: 10.3390/jcm11216286.
5
Efficacy of therapeutic plasma exchange in severe COVID-19 disease: A meta-analysis.
Vox Sang. 2023 Jan;118(1):49-58. doi: 10.1111/vox.13367. Epub 2022 Oct 18.
6
On Therapeutic Plasma Exchange Against Severe COVID-19-Associated Pneumonia: An Observational Clinical Study.
Front Nutr. 2022 Feb 22;9:809823. doi: 10.3389/fnut.2022.809823. eCollection 2022.
7
Therapeutic plasma exchange followed by convalescent plasma transfusion in severe and critically ill COVID-19 patients: A single centre non-randomized controlled trial.
Exp Ther Med. 2022 Jan;23(1):76. doi: 10.3892/etm.2021.10999. Epub 2021 Nov 24.
8
Application of extracorporeal therapies in critically ill COVID-19 patients.
J Zhejiang Univ Sci B. 2021;22(9):701-717. doi: 10.1631/jzus.B2100344.
9
Neuromuscular complications of coronavirus disease-19.
Curr Opin Neurol. 2021 Oct 1;34(5):669-674. doi: 10.1097/WCO.0000000000000970.
10
Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β.
J Clin Immunol. 2021 Oct;41(7):1425-1442. doi: 10.1007/s10875-021-01068-6. Epub 2021 Jun 8.
本文引用的文献
1
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.
N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21.
2
Endothelial cell infection and endotheliitis in COVID-19.
Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.
3
A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19.
Crit Care. 2020 Apr 2;24(1):128. doi: 10.1186/s13054-020-2836-4.
4
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
5
Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock.
Crit Care. 2020 Mar 2;24(1):71. doi: 10.1186/s13054-020-2799-5.
6
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.
J Clin Apher. 2019 Jun;34(3):171-354. doi: 10.1002/jca.21705.
7
Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers.
Crit Care. 2018 Oct 30;22(1):285. doi: 10.1186/s13054-018-2220-9.
8
Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A--an associated respiratory failure and hemodynamic shock.
Pediatr Crit Care Med. 2011 Mar;12(2):e87-9. doi: 10.1097/PCC.0b013e3181e2a569.
9
Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial.
Intensive Care Med. 2002 Oct;28(10):1434-9. doi: 10.1007/s00134-002-1410-7. Epub 2002 Jul 23.
Zotero 插件